Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. [Radium isotopes]

Conference · · Am. J. Obstet. Gynecol.; (United States)
OSTI ID:5333410

Hydroxyurea was evaluated as a possible radiation sensitizer in 130 evaluable women with Stages IIB and IIIB (International Federation of Gynecology and Obstetrics) carcinoma of the uterine cervix. This was a prospective double-blind randomized study in which hydroxyurea or placebo was compared in conjunction with continuous or split-course radiation therapy. Of all patients with Stage IIB cancer without biopsy proof of aortic node metastasis, a significant improvement in survival (P < 0.01) was achieved in the hydroxyurea group (74.0 per cent) as compared to the patients receiving placebo (43.5 per cent). In women with Stage IIIB cervical cancer there was a trend toward longer survival in those receiving hydroxyurea (52.1 per cent) as compared to those receiving placebo (33.3 per cent). However, there was a statistically significant improvement in survival in those women with Stage IIIB cervical cancer who had staging done at operation, were found to have negative para-aortic nodes, and subsequently received continuous radiation therapy (90.9 per cent) as compared to those receiving split-course therapy (29.4 per cent) (P = 0.005).

Research Organization:
Roswell Park Memorial Inst., Buffalo
OSTI ID:
5333410
Journal Information:
Am. J. Obstet. Gynecol.; (United States), Journal Name: Am. J. Obstet. Gynecol.; (United States) Vol. 129:4; ISSN AJOGA
Country of Publication:
United States
Language:
English